Serum ca 50 as a tumor marker in pancreatic cancer: A comparison with CA 19-9

✍ Scribed by Caj Haglund; Pentti Kuusela; Hannu Jalanko; Peter J. Roberts

• Publisher: John Wiley and Sons
• Year: 1987
• Tongue: French
• Weight: 459 KB
• Volume: 39
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910390412

✦ Synopsis

CA 50 is a new tumor marker based on a monoclonal anti-carcinoid tumor, 2 cystadenocarcinomas, 2 anaplastic carcibody (MAb) against a human colorectal carcinoma cell line.The nomas, 15 poorly differentiated and 39 well-to moderately-CA 50 antigen is similar, but not identical, to the tumor differentiated ductal adenocarcinomas. The exact degree of marker CA 19-9. The Serum concentrations of CA 50 were differentiation of 34 adenocarcinomas could not be determined measured by an immunoradiometric assay IRMA) in from available cytological samples. Ten of the tumors were 95 patients with pancreatic cancer and in 94 patients with benign pancreatic, biliary and hepatocellular diseases. The CA resectable, while the rest had spread locally or metastasized.

of the patients with pancreatic cancer. Elevated CA 50 levels tients, who later developed a recurrence.

were also seen in 29% of the patients with benign diseases (up Fifty-two patients had benign pancreatic disease: severe to 250 U/ml), especially in Patients with extra-hepatic thole-hemorrhagic pancreatitis (25 patients), non-hemorrhagic acute stasis (34%) and hepatocellular jaundice (46%). The results of pancreatitis (17), acute pancreatitis associated with pseudocyst commercially available CA 50 RIA inhibition test. The sensitivities of the two CA 50 assays for pancreatic cancer were tients had benign biliary tract diseases: stones in the common similar, but the specificity of the IRMA assay was higher. The bile duct with (11 patients) or without (4) cholestasis, post-CA 50 and CA 19-9 values showed a strong positive correlation operative stenosis with jaundice (one), and gall-bladder Stones and the assay parameters of the tests were almost similar. (13). Post-operative control samples were obtained from 3 of CA 50 seems a promising tumor marker in the detection and the patients with benign obstructive jaundice after recovery.

follow-up of patients with pancreatic cancer.